PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at

0001612940--12-312026Q1falseProQR Therapeutics N.V.6-K2026-03-31P10YP10YP11YP5YP30D0001612940prqr:PontifaxAndKreosWarrantsMember2022-09-012022-09-300001612940prqr:EliLillyAndCompanyMember2026-01-012026-03-310001612940prqr:SharePurchaseAgreementWithEliLillyAndCompanyMember2024-10-250001612940prqr:UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember2024-10-310001612940prqr:ShelfRegistrationStatement2024Member2024-09-300001612940prqr:AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember2024-09-300001612940prqr:RettSyndromeResearchTrustMember2024-01-310001612940prqr:RettSyndromeResearchTrustMember2024-12-310001612940prqr:OfficeAndLaboratoryFacilityMemberprqr:LeidenNetherlandsMember2020-07-012020-07-010001612940prqr:OfficeAndLaboratoryFacilityMemberprqr:LeidenNetherlandsMember2020-12-012020-12-310001612940prqr:OfficeAndLaboratoryFacilityMemberprqr:LeidenNetherlandsMember2026-01-012026-03-310001612940ifrs-full:IssuedCapitalMember2026-01-012026-03-310001612940ifrs-full:IssuedCapitalMember2025-01-012025-03-310001612940prqr:AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember2026-01-012026-03-310001612940prqr:UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember2024-10-312024-10-310001612940prqr:RettSyndromeResearchTrustMember2025-01-012025-03-310001612940prqr:UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember2024-10-012024-10-310001612940prqr:InnovationCreditMember2023-12-310001612940prqr:OfficeAndLaboratoryFacilityMemberprqr:LeidenNetherlandsMember2026-03-310001612940ifrs-full:OrdinarySharesMember2025-12-310001612940ifrs-full:LeaseholdImprovementsMember2026-03-310001612940ifrs-full:LeaseholdImprovementsMember2025-12-310001612940prqr:InnovationCreditMember2023-10-012023-12-310001612940prqr:RettSyndromeResearchTrustMember2026-01-012026-03-310001612940prqr:EliLillyAndCompanyMemberprqr:MilestonePaymentsMember2023-02-012023-02-280001612940prqr:EliLillyAndCompanyMember2021-10-012021-10-310001612940prqr:ProqrTherapeuticsViiiB.v.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsViiB.v.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsViB.v.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsVB.v.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsIxB.v.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsIvB.v.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsIInc.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsIiiB.v.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsIiB.v.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsIB.v.Member2026-01-012026-03-310001612940prqr:ProqrTherapeuticsHoldingB.v.Member2026-01-012026-03-310001612940prqr:SharePurchaseAgreementWithEliLillyAndCompanyMember2024-10-252024-10-250001612940prqr:EliLillyAndCompanyMember2022-12-012022-12-310001612940prqr:EliLillyAndCompanyMember2021-09-012021-09-300001612940prqr:October2024UnderwrittenPublicOfferingMember2024-10-012024-10-310001612940ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2026-01-012026-03-310001612940ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-03-310001612940ifrs-full:PreferenceSharesMember2026-03-310001612940ifrs-full:OrdinarySharesMember2026-03-310001612940prqr:InnovationCreditMember2018-10-120001612940ifrs-full:RetainedEarningsMember2026-01-012026-03-310001612940ifrs-full:ReserveOfSharebasedPaymentsMember2026-01-012026-03-310001612940ifrs-full:SharePremiumMember2025-01-012025-03-310001612940ifrs-full:RetainedEarningsMember2025-01-012025-03-310001612940ifrs-full:ReserveOfSharebasedPaymentsMember2025-01-012025-03-310001612940prqr:YarrowBiotechnologyMember2026-03-310001612940prqr:PhoenicisTherapeuticsIncMember2026-03-310001612940prqr:YarrowBiotechnologyMember2025-12-310001612940prqr:PhoenicisTherapeuticsIncMember2025-12-310001612940prqr:IfrsSellingGeneralAndAdministrativeExpensesMember2026-01-012026-03-310001612940prqr:IfrsResearchAndDevelopmentExpenseMember2026-01-012026-03-310001612940prqr:IfrsSellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001612940prqr:IfrsResearchAndDevelopmentExpenseMember2025-01-012025-03-310001612940ifrs-full:SharePremiumMember2026-03-310001612940ifrs-full:RetainedEarningsMember2026-03-310001612940ifrs-full:ReserveOfSharebasedPaymentsMember2026-03-310001612940ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2026-03-310001612940ifrs-full:IssuedCapitalMember2026-03-310001612940ifrs-full:SharePremiumMember2025-12-310001612940ifrs-full:RetainedEarningsMember2025-12-310001612940ifrs-full:ReserveOfSharebasedPaymentsMember2025-12-310001612940ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-12-310001612940ifrs-full:IssuedCapitalMember2025-12-310001612940ifrs-full:SharePremiumMember2025-03-310001612940ifrs-full:RetainedEarningsMember2025-03-310001612940ifrs-full:ReserveOfSharebasedPaymentsMember2025-03-310001612940ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-03-310001612940ifrs-full:IssuedCapitalMember2025-03-310001612940ifrs-full:SharePremiumMember2024-12-310001612940ifrs-full:RetainedEarningsMember2024-12-310001612940ifrs-full:ReserveOfSharebasedPaymentsMember2024-12-310001612940ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001612940ifrs-full:IssuedCapitalMember2024-12-310001612940prqr:EliLillyAndCompanyMember2021-09-300001612940prqr:EliLillyAndCompanyMember2026-03-310001612940prqr:EliLillyAndCompanyMember2025-12-3100016129402025-03-3100016129402024-12-310001612940prqr:InnovationCreditMember2026-03-310001612940prqr:InnovationCreditMember2025-12-3100016129402026-03-3100016129402025-12-3100016129402025-01-012025-03-3100016129402026-01-012026-03-31xbrli:sharesiso4217:EURiso4217:EURxbrli:sharesiso4217:USDxbrli:pureutr:sqmprqr:segmentiso4217:USDxbrli:shares

PROQR THERAPEUTICS N.V.

Index to Unaudited Condensed Consolidated Financial Statements

Unaudited Condensed Consolidated Financial Statements

PROQR THERAPEUTICS N.V.

Unaudited Condensed Consolidated Statement of Financial Position

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

Unaudited Condensed Consolidated Financial Statements

PROQR THERAPEUTICS N.V.

Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

( in thousands, except share and per share data)

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

Unaudited Condensed Consolidated Financial Statements

PROQR THERAPEUTICS N.V.

Unaudited Condensed Consolidated Statement of Changes in Equity

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

Unaudited Condensed Consolidated Financial Statements

PROQR THERAPEUTICS N.V.

Unaudited Condensed Consolidated Statement of Cash Flows

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

Unaudited Condensed Consolidated Financial Statements

PROQR THERAPEUTICS N.V.

Notes to Unaudited Condensed Consolidated Financial Statements

1. General Information

ProQR Therapeutics N.V., or "ProQR" or the "Company", is a biotechnology company domiciled in the Netherlands that primarily focuses on the discovery and development of novel therapeutic medicines.

Since September 18, 2014, the Company's ordinary shares have been listed on Nasdaq. They are currently trading at Nasdaq Capital Market under ticker symbol PRQR.

The Company was incorporated in the Netherlands, on February 21, 2012 (Chamber of Commerce no. 54600790) and was reorganized from a private company with limited liability to a public company with limited liability on September 23, 2014. The Company has its statutory seat in Leiden, the Netherlands. The address of its headquarters and registered office is Zernikedreef 9, 2333 CK Leiden, the Netherlands.

ProQR Therapeutics N.V. is the ultimate parent company of the following entities:

ProQR Therapeutics N.V. is also statutory director of Stichting Bewaarneming Aandelen ProQR ("ESOP Foundation") and has full control over this entity.

As used in these condensed consolidated financial statements, unless the context indicates otherwise, all references to "ProQR" or the "Company" refer to ProQR Therapeutics N.V. including its subsidiaries and the ESOP Foundation.

Unaudited Condensed Consolidated Financial Statements

2. Significant Accounting Policies

These interim condensed consolidated financial statements for the three month period ended March 31, 2026, have been prepared in accordance with IAS 34 Interim Financial Statements. They should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2025. These interim condensed consolidated financial statements do not include all information required for a complete set of financial statements prepared in accordance with IFRS Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the last annual financial statements. In the opinion of management, all events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period are disclosed in these interim condensed consolidated financial statements. The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those applied in the preparation of the Company's annual financial statements for the year ended December 31, 2025.

The Company's financial results have varied substantially, and are expected to continue to vary, from period to period. The Company believes that its ordinary activities are not linked to any particular seasonal factors.

The management of ProQR has, upon preparing and finalizing these interim condensed consolidated financial statements, assessed the Company's ability to fund its operations for a period of at least one year after the date of signing these interim condensed consolidated financial statements. Management expects the Company to continue as a going concern based on its existing funding, taking into account the Company's current cash position and the projected cash flows based on the activities under execution on the basis of ProQR's business plan and budget. The uncertainties and assumptions used are disclosed in Note 4. As a result, we continue to adopt the going concern basis of accounting in preparing the interim condensed consolidated financial statements.

The carrying amount of all financial assets and financial liabilities is a reasonable approximation of the fair value and therefore, information about the fair values of each class has not been disclosed.

The Company operates in one reportable segment, which comprises the discovery and development of innovative, RNA based therapeutics.

3. Adoption of New and Revised International Financial Reporting Standards

New Standards and Interpretations, which became effective as of January 1, 2026, did not have a material impact on our condensed consolidated financial statements.

Unaudited Condensed Consolidated Financial Statements

4. Critical Accounting Estimates and Judgements

In the application of the Company's accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

The significant judgements made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those described in the Company's annual financial statements for the year ended December 31, 2025.

(i) Revenue recognition for the Eli Lilly and Company research and collaboration agreement

a. Identification of the performance obligations

As further described in Note 13 the identification of the performance obligations for the Company's original research and collaboration agreement with Eli Lilly and Company ("Lilly"), and the amended and restated research and collaboration agreement (collectively, the "Collaboration agreement") involves significant judgement.

A key judgement was made in determining that the license granted to Lilly is not distinct from the associated research and development ("R&D") services, due to the lack of stand-alone value of the license without the Company's involvement and the significant interdependencies between the license and the R&D services to be provided by the Company. As a result, the license and the R&D services are accounted for together as a single combined performance obligation consisting of multiple activities that are not distinct.

b. Determining the timing of satisfaction of performance obligations

As further described in Note 13, before the handover of a compound to Lilly, the Company recognizes revenue over time, using an input method that estimates the satisfaction of the performance obligation as the percentage of labor hours incurred compared to the total estimated labor hours required to complete the promised services. As the Company's estimate of the total labor hours required is dependent on the evolution of the research and development activities, it may be subject to change. If the progression and/or outcome of certain research and development activities would be different from the assumptions that were made during the preparation of these financial statements, this could lead to material adjustments to the total estimated labor hours, which might result in a reallocation of revenue between current and future periods. Our total deferred revenue balance related to this Lilly performance obligation amounts to 36,914,000 at March 31, 2026 (December 31, 2025: 38,946,000).

c. Determining the transaction price

The Company applied judgement to determine whether the equity investments made by Lilly in ProQR are part of the transaction price for the Collaboration agreement. The Company concluded that the differences between the prices that Lilly paid for the shares and the ProQR stock closing prices on the days of entering into the equity investment agreements arose because of the Company's existing obligations to deliver research and development services to Lilly under the terms of the Collaboration agreement. Therefore, the above differences between the closing share prices on the agreement effective dates and the equity investment prices paid by Lilly are considered to be part of the transaction price of the contract and are initially allocated to deferred revenue.

Unaudited Condensed Consolidated Financial Statements

The contract also includes variable consideration, but no variable consideration was included in the initial transaction price at the inception, as it was not highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur. The Company includes such variable consideration in the transaction price when the uncertainty associated with the variable consideration is resolved.

The Collaboration agreement includes variable consideration in the form of development milestones, commercial milestones, and sales-based royalties based on the level of sales. As further described in Note 13, during 2026, the Company achieved development milestones during the ProQR research program under the agreement, which were added to the transaction price and recognized partially as revenue during 2026 based on the status of completion (satisfied part) of the single combined performance obligation.

(ii) Research and development expenditures

Research expenditures are reflected in the income statement. Development expenses are currently also reflected in the income statement because the criteria for capitalization are not met. Research and development costs are recognized as an expense when incurred and are typically made up of clinical and preclinical activities including costs for contract research organizations and clinical investigative sites.

Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided by vendors on their actual costs incurred. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed.

Although the Company does not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period.

The preparation of the interim condensed consolidated financial statements on a going concern basis requires management to make significant judgements about the Company's ability to continue as a going concern. In making this judgement, management has prepared cash flow forecasts covering a period of at least twelve months from the date of issuance of these financial statements. These forecasts are based on assumptions regarding the timing and progress of the Company's research and development activities and related expenditures. Changes in these assumptions could have a material impact on the Company's ability to continue as a going concern.

Additionally, the Company's current cash position is sensitive to potential delays in clinical trials and increases in development costs, which could affect the timing of cash outflows. While the Company has historically been able to raise additional funding, its ability to do so remains subject to market conditions. As at March 31, 2026, the Company had cash and cash equivalents of 81.1 million, which provides sufficient resources to continue operating activities for at least the twelve-month period following the issuance of these condensed consolidated financial statements. Based on the assessment performed, management has concluded that the use of the going concern basis of accounting is appropriate.

Unaudited Condensed Consolidated Financial Statements

5. Cash and Cash Equivalents

At March 31, 2026, the Company's cash and cash equivalents were 81,088,000 compared to 92,413,000 at December 31, 2025. The cash balances are held at banks with investment grade credit ratings. Short-term credit ratings must be rated A-1/P-1/F1 at a minimum by at least one of the Nationally Recognized Statistical Rating Organizations ("NRSROs") specifically Moody's, Standard & Poor's or Fitch. The cash at banks is at full disposal of the Company. Included in cash and cash equivalents are deposits fixed for at most 3-month periods at a time and money market funds which are invested in short-term government backed instruments with maturities up to three months at inception and are readily convertible to cash.

6. Trade and Other Receivables

All receivables are considered short-term and due within one year. At March 31, 2026 and December 31, 2025 collaboration receivables consisted of amounts receivable from Lilly. At March 31, 2026 and December 31, 2025 prepayments consisted principally of payments made by the Company for services not yet provided by vendors. At March 31, 2026 and December 31, 2025 other receivables consisted principally of accrued grant income and deposits. As at March 31, 2026 and December 31, 2025 the accrued grant income relating to Rett Syndrome Research Trust ("RSRT") includes the initial fair value of the warrants issued to RSRT that was accounted for as a reduction of the transaction price. The RSRT agreement is described in Note 14. Other Income.

7. Property, Plant and Equipment

At March 31, 2026 and December 31, 2025, property plant and equipment consisted of buildings and leasehold improvements, laboratory equipment and other assets. Buildings and leasehold improvements include a right-of-use asset relating to the lease of our Leiden office and laboratory space, with a carrying amount of 9,540,000 at March 31, 2026 (December 31, 2025: 9,994,000).

8. Other Current Liabilities

At March 31, 2026 other current liabilities amount to 8,421,000 (December 31, 2025: 7,940,000). At March 31, 2026 and December 31, 2025, other current liabilities consisted principally of accruals for services provided by vendors not yet billed, payroll related accruals and other miscellaneous liabilities.

Unaudited Condensed Consolidated Financial Statements

In December 2018, ProQR was awarded an Innovation credit for the sepofarsen program. Amounts were drawn under this facility from 2018 through 2022. The credit of 3,907,000 was used to conduct the Phase 2/3 clinical study and efforts to obtain regulatory and ethical market approval (New Drug Applications / Marketing Authorization Applications) of sepofarsen for LCA10. In the fourth quarter of 2023, ProQR made a partial repayment of the principal, amounting to 1,008,000. The remaining amount payable of 2,899,000 is recognized under current borrowings as at March 31, 2026 and December 31, 2025.

In December 2023, ProQR received a waiver to postpone repayment for the remaining balance of the Innovation credit including accrued interest. As a result, the repayment of the total loan of 4,292,000, including accrued interest, could be waived if conditions are met, subject to annual review. In December 2025, the waiver for the principal and interest was again extended until December 31, 2026.

In September 2022, ProQR extinguished its debt with Pontifax and Kreos by repaying all outstanding principal amounts. However, the Pontifax' and Kreos' warrants, classified as derivative financial instruments on the balance sheet, remain in place until their five-year economic life expires in 2025 and 2026. These warrants are accounted for as embedded derivatives and were recognized separately from the host contract as derivative financial liabilities at fair value through profit or loss. The warrants as part of the original loan agreement expired during 2025 and were derecognized. The warrants as part of the subsequent loan agreement remain in place until the economic life expires in December 2026.

10. Lease Liabilities

At March 31, 2026 and December 31, 2025, lease liabilities primarily consisted of the Company's lease of office and laboratory facilities at Zernikedreef in Leiden, the Netherlands.

The Company leases office and laboratory facilities of 4,818 square meters at Zernikedreef in Leiden, the Netherlands, where our headquarters and our laboratories are located. The current lease agreement for these facilities terminates on June 30, 2031. The lease agreement contains no significant dismantling requirements.

The initial 10-year lease agreement for the Leiden office and laboratory facilities was accounted for as of commencement date July 1, 2020. This 10-year period was extended by 1 year to an 11-year period in December 2020. The lease contract may be extended for subsequent 5-year periods. As the Company is not reasonably certain to exercise these extension options, these are not included in the lease term.

The carrying amount of the right-of-use asset is disclosed in Note 7.

Unaudited Condensed Consolidated Financial Statements

The following table summarizes details of deferred income at March 31, 2026 and December 31, 2025. The nature of the deferred income is described in Note 13 and 14.

12. Shareholders' Equity

The authorized share capital of the Company amounting to 13,600,000 consists of 170,000,000 ordinary shares and 170,000,000 preference shares with a par value of 0.04 per share. At March 31, 2026, 107,710,916 ordinary shares were issued, which is comprised of 105,362,551 ordinary shares fully paid and outstanding as well as 2,348,365 ordinary shares held by the Company as treasury shares (December 31, 2025: 2,349,852). These treasury shares are issued and not outstanding.

In September 2024, the Company filed a shelf registration statement on Form F-3, which permitted: (a) the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $ 300,000,000 of its ordinary shares, warrants and/or units; and (b) as part of the $ 300,000,000, the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $ 75,000,000 of its ordinary shares that may be issued and sold under a sales agreement (the "sales agreement") with Cantor Fitzgerald & Co. ("Cantor") in one or more at-the-market ("ATM") offerings. The Company will pay Cantor a commission equal to 3% of the gross proceeds of the sales price of all ordinary shares sold through it as sales agent under the sale agreement. As of March 31, 2026 no shares have been issued pursuant to this ATM facility.

In October 2024, the Company consummated an underwritten public offering of 18,000,000 ordinary shares (the "offering") at a public offering price of $ 3.50 per share (the "public offering price"). In addition, the Company granted the underwriters a 30-day option to purchase up to 2,700,000 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The option was partially exercised on October 31, 2024, resulting in the issuance of 1,940,072 shares. The gross proceeds from the Offering and subsequent partial exercise of the underwriters' option, amounted to $ 69,790,000 ( 64,600,000) while the transaction costs amounted to approximately 4,365,000, resulting in net proceeds of approximately 60,235,000.

Unaudited Condensed Consolidated Financial Statements

Concurrently with the Offering, the Company entered into a share purchase agreement with Lilly in a separately negotiated transaction (the "concurrent private placement"), pursuant to which the Company agreed to offer and sell, and Lilly agreed to purchase, 3,523,538 ordinary shares at a price per share equal to the public offering price, for total gross proceeds of approximately $ 12,300,000, subject to a purchase price cap of $ 15,000,000, the consummation of the Offering and the satisfaction of other customary closing conditions. The proceeds of $ 12,300,000 ( 11,400,000) from the concurrent private placement were received on October 25, 2024. The ordinary shares purchased in the concurrent private placement are not subject to any underwriting discounts or commissions.

The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.

The Company operates an equity-settled share-based compensation plan, which was introduced in 2013. Options and Restricted Stock Units ("RSUs") may be granted to employees, members of the Board and consultants. The compensation expenses included in operating costs for this plan in the three month period ended March 31, 2026 were 1,428,000 (three month period ended March 31, 2025: 758,000), of which 1,038,000 was recorded in general and administrative costs (three month period ended March 31, 2025: 566,000) and 390,000 was recorded in research and development costs (three month period ended March 31, 2025: 192,000).

Eli Lilly and Company collaboration

In September 2021, the Company entered into a global licensing and research collaboration with Lilly focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR and Lilly will use ProQR's proprietary Axiomer RNA editing platform to progress new drug targets toward clinical development and commercialization.

Under the terms of the agreement, ProQR received an upfront payment and equity consideration, and is eligible to receive milestone payments and royalties on the net sales of any resulting products. In September 2021, the Company issued 3,989,976 shares to Lilly, resulting in gross proceeds of $ 30,000,000 ( 25,270,000). These shares were issued at a premium of $ 2,429,000 ( 2,047,000), which was determined to be part of the transaction price and as such was initially recognized as deferred revenue. An up-front payment of $ 20,000,000 ( 16,849,000) was received in October 2021.